JAY WALTER HEINECKE
Osteopathic Medicine at Pacific St, Seattle, WA
License number
Washington MD00020145
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
1959 NE Pacific St, Seattle, WA 98195
Phone
(206) 598-4333
Personal information
See more information about JAY WALTER HEINECKE at radaris.comName
Address
Phone
2351 Yale Ave E #A, Seattle, WA 98102
2351 Yale Ave E, Seattle, WA 98102
Seattle, WA
117 57Th St, Seattle, WA 98105
Professional information
Methods And Compositions For Diagnosis Or Prognosis Of Cardiovascular Disease
US Patent:
8241861, Aug 14, 2012
Filed:
Jul 8, 2009
Appl. No.:
12/499711
Inventors:
Jay W. Heinecke - Seattle WA, US
Tomas Vaisar - Bellevue WA, US
Bryan Prazen - Seattle WA, US
Erik Nilsson - Seattle WA, US
Tomas Vaisar - Bellevue WA, US
Bryan Prazen - Seattle WA, US
Erik Nilsson - Seattle WA, US
Assignee:
Insilicos, LLC - Seattle WA
University of Washington - Seattle WA
University of Washington - Seattle WA
International Classification:
G01N 31/00, G01N 33/53
US Classification:
435 721, 435 71, 436501, 436518, 424 91, 424520, 422 50, 530300, 530350
Abstract:
The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop or is suffering from, cardiovascular disease. In one embodiment, the method comprises detecting a measurable feature of at least two biomarkers in an HDL subfraction, or in a complex containing apoA-I or apoA-II isolated from a biological sample obtained from the subject, wherein the at least two biomarkers are selected from the group consisting of apoA-I, apoA-II, apoB-100, Lp(a), apoC-I, and apoC-III, combinations or portions and/or derivatives thereof, and comparing the measurable features of the at least two biomarkers from the biological sample to a reference standard, wherein a difference in the measurable features of the at least two biomarkers from the biological sample and the reference standard is indicative of the presence or risk of cardiovascular disease in the subject.
Methods And Compositions For Diagnosis Or Prognosis Of Cardiovascular Disease
US Patent:
8460889, Jun 11, 2013
Filed:
Jul 6, 2012
Appl. No.:
13/543745
Inventors:
Jay W. Heinecke - Seattle WA, US
Tomas Vaisar - Bellevue WA, US
Bryan Prazen - Seattle WA, US
Erik Nilsson - Seattle WA, US
Tomas Vaisar - Bellevue WA, US
Bryan Prazen - Seattle WA, US
Erik Nilsson - Seattle WA, US
Assignee:
University of Washington - Seattle WA
Insilicos, LLC - Seattle WA
Insilicos, LLC - Seattle WA
International Classification:
G01N 33/53, G01N 31/00
US Classification:
435 721, 435 71, 436501, 436518, 422 50, 422430, 530300, 530350
Abstract:
The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop or is suffering from, cardiovascular disease. In one embodiment, the method comprises detecting a measurable feature of at least two biomarkers in an HDL subfraction, or in a complex containing apoA-I or apoA-III isolated from a biological sample obtained from the subject, wherein the at least two biomarkers are selected from the group consisting of apoA-I, apoA-II, apoB-100, Lp(a), apoC-I, and apoC-III, combinations or portions and/or derivatives thereof, and comparing the measurable features of the at least two biomarkers from the biological sample to a reference standard, wherein a difference in the measurable features of the at least two biomarkers from the biological sample and the reference standard is indicative of the presence or risk of cardiovascular disease in the subject.
Jay Walter Heinecke, Seattle WA
Specialties:
Internal Medicine, Endocrinology and Metabolism, Endocrinology, Diabetes & Metabolism
Work:
University Of Washington Medical Ctr
1959 Ne Pacific St, Seattle, WA 98195
1959 Ne Pacific St, Seattle, WA 98195
Education:
(1981)
Methods For Assessing The Risk For Development Of Cardiovascular Disease
US Patent:
2010029, Nov 25, 2010
Filed:
May 21, 2010
Appl. No.:
12/785332
Inventors:
Jay W. Heinecke - Seattle WA, US
John F. Oram - Seattle WA, US
John F. Oram - Seattle WA, US
Assignee:
University of Washington - Seattle WA
International Classification:
G01N 33/53, C12Q 1/02, G01N 33/92, G01N 33/543, G01N 33/68, G01N 33/50, G01N 27/447
US Classification:
435 792, 435 29, 435 71, 436 71, 436518, 436 86, 436129, 204451
Abstract:
The present invention relates to diagnostic tests, methods and kits that are useful to assess a subject's risk of developing a pathologic condition related in part to the presence of HDL oxidation product. Measuring the quantity of one or more HDL oxidation products present in the blood is useful in evaluating risk for developing or evaluating the severity of a disease or evaluating response to treatment for such a disease as, for instance, cardiovascular disease.
Methods For Assessing The Risk For Development Of Cardiovascular Disease
US Patent:
7749729, Jul 6, 2010
Filed:
Jul 19, 2005
Appl. No.:
11/572308
Inventors:
Jay W. Heinecke - Seattle WA, US
John F. Oram - Seattle WA, US
John F. Oram - Seattle WA, US
Assignee:
University of Washington - Seattle WA
International Classification:
G01N 33/53
US Classification:
435 41
Abstract:
The present invention relates to diagnostic tests, methods and kits that are useful to assess a subject's risk of developing a pathologic condition related in part to the presence of HDL oxidation product. Measuring the quantity of one or more HDL oxidation products present in the blood is useful in evaluating risk for developing or evaluating the severity of a disease or evaluating response to treatment for such a disease as, for instance, cardiovascular disease.
Lipoprotein-Associated Markers For Cardiovascular Disease
US Patent:
7972802, Jul 5, 2011
Filed:
Oct 31, 2005
Appl. No.:
11/263553
Inventors:
Jay W. Heinecke - Seattle WA, US
Tomas Vaisar - Bellevue WA, US
Tomas Vaisar - Bellevue WA, US
Assignee:
University of Washington - Seattle WA
International Classification:
G01N 1/00, G01N 33/53
US Classification:
435 721, 435 71, 436501, 436518
Abstract:
The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop, or is suffering from, cardiovascular disease. The methods comprise detecting an amount of at least one biomarker in a biological sample, or HDL subfraction thereof, from the subject, and comparing the detected amount of the biomarker to a predetermined value, where a difference between the detected amount and the predetermined value is indicative of the presence or risk of cardiovascular disease in the subject. In some embodiments, the biomarker comprises at least one of ApoC-IV, Paraoxonase 1, C3, C4, ApoA-IV, ApoE, ApoL1, C4B1, Histone H2A, ApoC-II, ApoM, Vitronectin, Haptoglobin-related protein, and Clusterin, or combinations thereof.
Lipoprotein-Associated Markers For Cardiovascular Disease
US Patent:
8420337, Apr 16, 2013
Filed:
May 10, 2011
Appl. No.:
13/104757
Inventors:
Jay W. Heinecke - Seattle WA, US
Tomas Vaisar - Bellevue WA, US
Tomas Vaisar - Bellevue WA, US
Assignee:
University of Washington - Seattle WA
International Classification:
G01N 31/00, G01N 33/53
US Classification:
435 721, 435 71, 436501, 436518
Abstract:
The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop, or is suffering from, cardiovascular disease. The methods comprise detecting an amount of at least one biomarker in a biological sample, or HDL subfraction thereof, from the subject, and comparing the detected amount of the biomarker to a predetermined value, where a difference between the detected amount and the predetermined value is indicative of the presence or risk of cardiovascular disease in the subject. In some embodiments, the biomarker comprises at least one of ApoC-IV, Paraoxonase 1, C3, C4, ApoA-IV, ApoE, ApoL1, C4B1, Histone H2A, ApoC-II, ApoM, Vitronectin, Haptoglobin-related protein, and Clusterin, or combinations thereof.
Dr. Jay W Heinecke, Seattle WA - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
850 Republican St, Seattle 98109
1959 NE Pacific St SUITE 356426, Seattle 98195
(206) 598-4333 (Phone)
1959 NE Pacific St SUITE 356426, Seattle 98195
(206) 598-4333 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 1987, Internal Medicine, 1986
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
850 Republican St, Seattle 98109
1959 NE Pacific St SUITE 356426, Seattle 98195
University of Washington Medical Center
1959 East Pacific St, Seattle 98195
1959 NE Pacific St SUITE 356426, Seattle 98195
University of Washington Medical Center
1959 East Pacific St, Seattle 98195
Education:
Medical School
Washington Center / School of Medicine
Graduated: 1981
University Of Washington
Washington Center / School of Medicine
Graduated: 1981
University Of Washington
Mutant Apolipoprotein A-1 Polypeptide With Increased Resistance To Oxidation And Reactive Carbonyls
US Patent:
8541236, Sep 24, 2013
Filed:
Dec 6, 2007
Appl. No.:
11/952044
Inventors:
Jay W. Heinecke - Seattle WA, US
John F. Oram - Seattle WA, US
Michael N. Oda - Fairfield CA, US
John F. Oram - Seattle WA, US
Michael N. Oda - Fairfield CA, US
Assignee:
University of Washington - Seattle WA
The Children's Hospital & Research Center At Oakland - Oakland CA
The Children's Hospital & Research Center At Oakland - Oakland CA
International Classification:
C12N 15/00, C12P 21/06, A61K 38/00, A61K 38/16, C07K 14/775
US Classification:
435440, 435 691, 514 74, 514 212, 530350
Abstract:
In one aspect, the present invention provides isolated oxidation resistant mutant apoA-I polypeptides comprising an amino acid sequence substantially homologous to SEQ ID NO:4, the mutant apoA-I polypeptide comprising a combination of: (1) a conservative amino acid substitution at residue Tyr192; and (2) at least one conservative amino acid substitution at residue Met86, Met112, or Met148, wherein the mutant apoA-I polypeptide is resistant to modification by an oxidizing agent. In another aspect, the invention provides a method of promoting cholesterol efflux activity in a mammalian subject in need thereof, the method comprising the step of administering an effective amount of an oxidation resistant apoA-I agonist to the subject to promote cholesterol efflux.
Method For Detecting Conditions Indicative Of Sepsis
US Patent:
6939716, Sep 6, 2005
Filed:
Aug 22, 2002
Appl. No.:
10/225700
Inventors:
Jay W. Heinecke - Seattle WA, US
Assignee:
Washington University - St. Louis MO
International Classification:
G01N033/00
US Classification:
436 89, 436173, 436811, 435 71, 435 792, 435 4052, 435 696
Abstract:
The disclosure describes a method for detecting conditions indicative of sepsis. In one embodiment of the invention, an increase in the level of 3-chlorotyrosine or 3-bromotyrosine from the normal level in a sample of body fluid or tissue is indicative of early sepsis or infection. In another embodiment of the invention, the level of 3-chlorotyrosine or 3-bromotyrosine is measured or monitored to determine the response to therapeutic treatment of the infective condition in which a reduction in the level that existed prior to the treatment is an early sign or indication that the treatment is working in vivo. In a preferred embodiment, the method of the invention is illustrated in a clinically relevant mouse model of sepsis.
Osteopathic Medicine licenses in Washington
SEATTLE MEDICAL ASSOCIATES PLLP, Osteopathic Medicine, 1124 Columbia St SUITE 620, Seattle, WA 98104